ReviewNeuro-ophthalmology (Aeolus Press)2017
Amiodarone-Associated Optic Neuropathy: Clinical Review.
Review in Neuro-ophthalmology (Aeolus Press), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Unexplained Perivascular Chorioretinal Atrophy: Is Ranolazine a Possible Cause?Journal of ophthalmic & vision research · 2026Article
- Amiodarone-related keratopathy and optic neuropathy: case report and literature review.Frontiers in medicine · 2025Article
- Bio-spectroscopic investigation linking changes of retinal structure with short-term administration of Amiodarone and revealing the ameliorative effect of vitamin E supplementation.Scientific reports · 2024Article
- Article
- Optic neuropathy diagnosis in the emergency room - retrospective observational study of the last 18 years.European journal of ophthalmology · 2024Observational
- Adverse Ocular Effects of Systemic Medications.Life (Basel, Switzerland) · 2023Review
- Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy.Biomolecules · 2022Review
- Risk Factors of Eye Complications in Patients Treated in the Intensive Care Unit.International journal of environmental research and public health · 2021Article
- Optic neuropathy secondary to perhexiline and amiodarone.BMJ case reports · 2021Article
- Amiodarone-associated Optic Neuropathy-A Clinical Criteria-based Diagnosis?Neuro-ophthalmology (Aeolus Press) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amiodarone, an antiarrhythmic agent, has been associated with visual loss secondary to optic neuropathy. The reported mean duration of amiodarone use before visual loss is about 9 months. Patients receiving amiodarone have a 2-fold increased risk of developing optic neuropathy, especially in males and possibly in patients with longer duration of treatment. Amiodarone-associated optic neuropathy is characterised by an insidious onset, slow progression, bilateral simultaneous visual loss, and protracted disc swelling. After discontinuing amiodarone use, visual acuity and visual field deficits tend to improve or stabilise in most patients, with about 20% of the patients getting worse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.